Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers.

Next Previous
Search
Trial Profile

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Rifabutin; Rifampicin
  • Indications HIV-1 infections; Mycobacterium avium complex infections; Tuberculosis
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline; ViiV Healthcare

Most Recent Events

  • 21 Dec 2011 Actual patient number changed from 26 to 27 as reported by ClinicalTrials.gov.
  • 08 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 02 Dec 2011 Planned end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top